Advertisement

Reply to comment: Von Willebrand factor measurement during acute decompensation

  • Mattias Mandorfer
    Correspondence
    Corresponding author at: Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
    Affiliations
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Search for articles by this author
  • Katharina Pomej
    Affiliations
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Search for articles by this author
  • Bernhard Scheiner
    Affiliations
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Search for articles by this author
  • Lorenz Balcar
    Affiliations
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Search for articles by this author
  • Thomas Reiberger
    Affiliations
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Search for articles by this author
Published:November 12, 2022DOI:https://doi.org/10.1016/j.dld.2022.10.021
      We would like to thank Dr. Zanetto and colleagues for their interest in our work and for sharing their valuable findings in regard to plasma von Willebrand factor antigen (VWF:Ag) levels in patients with acute decompensation (AD) and their lack of association with acute-on-chronic liver failure (ACLF) development and death [
      • Zanetto A.C.E
      • Bulato C.
      • Burra P.
      • Senzolo M.
      • Simioni P
      Von Willebrand factor in hospitalized patients with acute decompensation of cirrhosis is increased but not associated with development of ACLF.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zanetto A.C.E
        • Bulato C.
        • Burra P.
        • Senzolo M.
        • Simioni P
        Von Willebrand factor in hospitalized patients with acute decompensation of cirrhosis is increased but not associated with development of ACLF.
        Dig Liver Dis. 2022; (in print)https://doi.org/10.1016/j.dld.2022.10.001
        • Mandorfer M.
        • Schwabl P.
        • Paternostro R.
        • Pomej K.
        • Bauer D.
        • Thaler J.
        • et al.
        Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.
        Aliment Pharmacol Ther. 2018; 47: 980-988
        • Pomej K.
        • Scheiner B.
        • Balcar L.
        • Nussbaumer R.J.
        • Weinzierl J.
        • Paternostro R.
        • et al.
        Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease.
        Dig Liver Dis. 2022; 54: 1376-1384
        • Reuken P.A.
        • Kussmann A.
        • Kiehntopf M.
        • Budde U.
        • Stallmach A.
        • Claus R.A.
        • et al.
        Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis.
        Liver Int. 2015; 35 (official journal of the International Association for the Study of the Liver): 37-45
        • Jachs M.
        • Hartl L.
        • Simbrunner B.
        • Bauer D.
        • Paternostro R.
        • Scheiner B.
        • et al.
        Decreasing von Willebrand factor levels upon nonselective beta blocker therapy indicate a decreased risk of further decompensation, acute-on-chronic liver failure, and death.
        Clin Gastroenterol Hepatol. 2022; 20 (the official clinical practice journal of the American Gastroenterological Association): 1362-1373
        • Trebicka J.
        • Fernandez J.
        • Papp M.
        • Caraceni P.
        • Laleman W.
        • Gambino C.
        • et al.
        The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.
        J Hepatol. 2020; 73: 842-854
        • Balcar L.
        • Semmler G.
        • Pomej K.
        • Simbrunner B.
        • Bauer D.
        • Hartl L.
        • et al.
        Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure.
        United Eur Gastroenterol J. 2021; 9: 427-437
        • Lisman T.
        • Arefaine B.
        • Adelmeijer J.
        • Zamalloa A.
        • Corcoran E.
        • Smith J.G.
        • et al.
        Global hemostatic status in patients with acute-on-chronic liver failure and septics without underlying liver disease.
        J Thromb Haemost JTH. 2021; 19: 85-95
        • Zanetto A.
        • Pelizzaro F.
        • Campello E.
        • Bulato C.
        • Balcar L.
        • Gu W.
        • et al.
        Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis.
        J Hepatol. 2022; (In press)
        • Scheiner B.
        • Balcar L.
        • Nussbaumer R.J.
        • Weinzierl J.
        • Paternostro R.
        • Simbrunner B.
        • et al.
        Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
        J Hepatol. 2022; 76: 1090-1099
        • Mandorfer M.
        • Hernández-Gea V.
        • García-Pagán J.C.
        • Reiberger T.
        Noninvasive diagnostics for portal hypertension: a comprehensive review.
        Semin Liver Dis. 2020; 40: 240-255
        • Jachs M.
        • Hartl L.
        • Simbrunner B.
        • Bauer D.
        • Paternostro R.
        • Scheiner B.
        • et al.
        The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension.
        Clin Gastroenterol Hepatol. 2022; (the official clinical practice journal of the American Gastroenterological Association In press)
        • Starlinger P.
        • Ahn J.C.
        • Mullan A.
        • Gyoeri G.P.
        • Pereyra D.
        • Alva-Ruiz R.
        • et al.
        The addition of C-reactive protein and von willebrand factor to MELD-Na improves prediction of waitlist mortality.
        Hepatology. 2021; 74 (Baltimore, Md): 1533-1545

      Linked Article